tbuckley/cabot-search huggingface dataset:
Prenatal exercise is not associated with fetal mortality: a systematic review and meta-analysis
Authors: Margie H Davenport, Amariah J Kathol, Michelle F Mottola, Rachel J Skow, Victoria L Meah, Veronica J Poitras, Alejandra Jaramillo Garcia, Casey E Gray, Nick Barrowman, Laurel Riske, Frances Sobierajski, Marina James, Taniya Nagpal, Andree-Anne Marchand, Linda G Slater, Kristi B Adamo, Gregory A Davies, Ruben Barakat, Stephanie-May Ruchat
Journal: British Journal of Sports Medicine (2018)

Objective To perform a systematic review of the relationship between prenatal exercise and fetal or newborn death. Design Systematic review with random-effects meta-analysis and meta-regression. Data sources Online databases were searched up to 6 January 2017. Study eligibility criteria Studies of all designs were included (except case studies) if they were published in English, Spanish or French and contained information on the population (pregnant women without contraindication to exercise), intervention (subjective or objective measures of frequency, intensity, duration, volume or type of exercise, alone [“exercise-only”] or in combination with other intervention components [eg, dietary; “exercise + co-intervention”]), comparator (no exercise or different frequency, intensity, duration, volume and type of exercise) and outcome (miscarriage or perinatal mortality). Results Forty-six studies (n=2 66 778) were included. There was ‘very low’ quality evidence suggesting no increased odds of miscarriage (23 studies, n=7125 women; OR 0.88, 95% CI 0.63 to 1.21, I 2 =0%) or perinatal mortality (13 studies, n=6837 women, OR 0.86, 95% CI 0.49 to 1.52, I 2 =0%) in pregnant women who exercised compared with those who did not. Stratification by subgroups did not affect odds of miscarriage or perinatal mortality. The meta-regressions identified no associations between volume, intensity or frequency of exercise and fetal or newborn death. As the majority of included studies examined the impact of moderate intensity exercise to a maximum duration of 60 min, we cannot comment on the effect of longer periods of exercise. Summary/conclusions Although the evidence in this field is of ‘very low’ quality, it suggests that prenatal exercise is not associated with increased odds of miscarriage or perinatal mortality. In plain terms, this suggests that generally speaking exercise is ‘safe’ with respect to miscarriage and perinatal mortality.
GW29-e0464 Accumulated Effect of Active Smoking combined with Family Smoking Increased Risk of Peripheral Arterial Disease: Results from National Health and Nutrition Examination Survey 1999-2004
Authors: Xiaodong Zhuang, Xiuting Sun, Daya Yang, Huimin Zhou, Shaozhao Zhang, Xiangbin Zhong, Xinxue Liao
Journal: Journal of the American College of Cardiology (2018)
Intelligent treatment decision support combining variant interpretation and phenotype analytics can transform healthcare
Authors: Theodoros Soldatos, Udo Schmidt-Edelkraut, Katrin Stecker, Carolin Huelsewig, Anna Laib, Sajo Kaduthanam, Miguel Cordova, Peter Koch, Matthias Loehr, David Jackson, Xiaoyue Wang, Michael Weber, Stephan Brock, Stephan Hettich
Journal: Annals of Oncology (2018)
PET-CT as a prognostic factor in patients with early stages in primary diagnosed Hodgkin lymphoma
Authors: T. Skrypets, O. Novosad, I. Pastushenko, T. Kadnikova, O. Gorbach, Y. Kmetyuk, O. Karpova, L. Mykhalska, E. Lukjanec, V. Kozlov, N. Novikov, O. Oliinichenko, N. Kostiukova, O. Tkachenko, O. Karnabeda, V. Stratienko, I. Kriachok
Journal: Annals of Oncology (2018)
Alterations of brain local functional connectivity in amnestic mild cognitive impairment
Authors: Dan Zheng, Wei Xia, Zhong Quan Yi, Pan Wen Zhao, Jian Guo Zhong, Hai Cun Shi, Hua Liang Li, Zhen Yu Dai, Ping Lei Pan
Journal: Translational Neurodegeneration (2018)

Resting-state functional magnetic resonance imaging studies using a regional homogeneity (ReHo) method have reported that amnestic mild cognitive impairment (aMCI) was associated with abnormalities in local functional connectivity. However, their results were not conclusive.Seed-based d Mapping was used to conduct a coordinate-based meta-analysis to identify consistent ReHo alterations in aMCI.We identified 10 studies with 11 datasets suitable for inclusion, including 378 patients with aMCI and 435 healthy controls. This meta-analysis identified significant ReHo alterations in patients with aMCI relative to healthy controls, mainly within the default mode network (DMN) (bilateral posterior cingulate cortex [PCC], right angular gyrus, bilateral middle temporal gyri, and left parahippocampal gyrus/hippocampus), executive control network (right superior parietal lobule and dorsolateral prefrontal cortex), visual network (right lingual gyrus and left middle occipital gyrus), and sensorimotor network (right paracentral lobule/supplementary motor area, right postcentral gyrus and left posterior insula). Significant heterogeneity of ReHo alterations in the bilateral PCC, left parahippocampal gyrus/hippocampus, and right superior parietal lobule/angular gyrus was observed. Exploratory meta-regression analyses indicated that general cognitive function, gender distribution, age, and education level partially contributed to this heterogeneity.This study provides provisional evidence that aMCI is associated with abnormal ReHo within the DMN, executive control network, visual network, and sensorimotor network. These local functional connectivity alterations suggest coexistence of functional deficits and compensation in these networks. These findings contribute to the modeling of brain functional connectomes and to a better understanding of the neural substrates of aMCI. Confounding factors merit much attention and warrant future investigations.
Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells
Authors: David M. Ross, Ilaria S. Pagani, Naranie Shanmuganathan, Chung H. Kok, John F. Seymour, Anthony K. Mills, Robin J. Filshie, Christopher K. Arthur, Phuong Dang, Verity A. Saunders, Jodi Braley, Agnes S. Yong, David T. Yeung, Deborah L. White, Andrew P. Grigg, Anthony P. Schwarer, Susan Branford, Timothy P. Hughes
Journal: Leukemia (2018)
Cardiopulmonary Exercise Testing Provides Additional Prognostic Information in Cystic Fibrosis
Authors: Helge Hebestreit, Erik H. J. Hulzebos, Jane E. Schneiderman, Chantal Karila, Steven R. Boas, Susi Kriemler, Tiffany Dwyer, Margareta Sahlberg, Don S. Urquhart, Larry C. Lands, Felix Ratjen, Tim Takken, Liobou Varanistkaya, Viktoria Rücker, Alexandra Hebestreit, Jakob Usemann, Thomas Radtke, Sibylle Junge, Christine Smaczny, Sarah Rand, Charlotte Dawson
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

The prognostic value of cardiopulmonary exercise testing (CPET) for survival in cystic fibrosis (CF) in the context of current clinical management, when controlling for other known prognostic factors, is unclear.To determine the prognostic value of CPET-derived measures beyond peak oxygen uptake ( V. o2peak) following rigorous adjustment for other predictors.Data from 10 CF centers in Australia, Europe, and North America were collected retrospectively. A total of 510 patients completed a cycle CPET between January 2000 and December 2007, of which 433 fulfilled the criteria for a maximal effort. Time to death/lung transplantation was analyzed using Cox proportional hazards regression. In addition, phenotyping using hierarchical Ward clustering was performed to characterize high-risk subgroups.Cox regression showed, even after adjustment for sex, FEV1% predicted, body mass index (z-score), age at CPET, Pseudomonas aeruginosa status, and CF-related diabetes as covariates in the model, that V. o2peak in % predicted (hazard ratio [HR], 0.964; 95% confidence interval [CI], 0.944-0.986), peak work rate (% predicted; HR, 0.969; 95% CI, 0.951-0.988), ventilatory equivalent for oxygen (HR, 1.085; 95% CI, 1.041-1.132), and carbon dioxide (HR, 1.060; 95% CI, 1.007-1.115) (all P < 0.05) were significant predictors of death or lung transplantation at 10-year follow-up. Phenotyping revealed that CPET-derived measures were important for clustering. We identified a high-risk cluster characterized by poor lung function, nutritional status, and exercise capacity.CPET provides additional prognostic information to established predictors of death/lung transplantation in CF. High-risk patients may especially benefit from regular monitoring of exercise capacity and exercise counseling.
Can a homeopathic medicine complex reduce hot flashes induced by adjuvant endocrine therapy in localized breast cancer patients? Results of a randomized placebo-controlled phase III trial.
Authors: Pierre-Etienne Heudel, Isabelle Van Praagh, Bernard Duvert, Isabelle Cauvin, Anne-Claire Hardy-Bessard, Jean-Philippe Jacquin, Laetitia Stefani, Aurelie Belliere, Lionel Vincent, Dominique Dramais, Jean-Paul Guastalla, Ellen Blanc, Aurelie Belleville, Emilie Lavergne, David Pérol
Journal: Journal of Clinical Oncology (2015)

9627 Background: Homeopathy is already used for the management of menopausal hot flashes (HF) and could reduce this frequent endocrine therapy’s (ET) side effect. Methods: Localized breast cancer patients (pts), treated for at least one month with adjuvant ET and complaining of HF were included in a multicentric randomized double-blind phase III study. Primary endpoint, analyzed in an intent-to-treat basis, was the variation of HF score (HFS) between pre and 4 weeks (w) post randomization. HFS was calculated (over 1 w) as the mean of HF frequency, weighted by a 4-level intensity scale. After a run-in period of placebo (2-4 w to exclude pts with strong placebo effect), only pts maintaining a HFS ≥ 10 were randomized to receive Actheane (a homeopathic medicine complex BRN-01) (A) vs Placebo (P) during 2 months. The trial was powered (90% power, two-sided alpha of 5%) to detect a 5-point (± 8.6) difference of HFS variation between arms; 138 randomized pts were needed. Secondary endpoints were HFS variation after 8 w of treatment, compliance, tolerance, quality of life (QoL) and satisfaction of pts. Results: From February 2010 to April 2014, 299 pts were included and 138 (46.2%) randomized (65 to A and 73 to P). Patients’ characteristics were well balanced between groups. Median age was 51 years [range 36-72], 82 pts were postmenopausal, 79 were treated by tamoxifen and 59 by aromatase inhibitor. No statistical difference was observed in HFS variation after 4 w (median of -2.9 points for A vs -2.5 for P; p = 0.76, corresponding to a median decrease of 17.2% vs 15.4% of HFS). However, HFS decreased for 75.4% of pts in A arm vs 67.6% in P. QoL score after 4 w was stable or improved for respectively 71.7% vs 73.9% of pts. Compliance to study treatment was similar between the 2 arms (82% for A vs 85% for P, p = 0.61). None of the 3 grade 3 adverse events declared (1 cholecystitis and 2 joint pains) were related to treatment. Conclusions: Although efficacy hypothesis was not reached, the management of HF globally decreased HFS, with positive impact on QoL. Because HF are a disabling symptom without validated treatment, Actheane could be a well-tolerated therapeutic option. Clinical trial information: NCT01246427.
Concomitant classic Hodgkin lymphoma and schistosomiasis
Authors: Waihay J. Wong, Deogratias Ruhangaza, Alexis Manirakiza, Jack Omondi, Marcellin C. Mugabe, Izimukwiye Isabelle, Elizabeth A. Morgan, Jon C. Aster
Journal: American Journal of Hematology (2018)

An 11-year-old boy in Rwanda presented with a 3-month history of weight loss, fevers, and abdominal pain. Physical examination revealed a marasmic male with a large hypogastric mass and bilateral lower extremity edema. Urine and stool analyses were negative for ova and parasites. Ultrasound imaging revealed an 18 cm mesenteric mass compressing the left kidney and diffuse abdominopelvic lymphadenopathy. An excisional biopsy of the mass revealed Schistosoma mansoni larvae dispersed in a fibrous stroma with numerous macrophages, lymphocytes, and eosinophils (Image 1A-1B). Also scattered among the inflammatory cells were large multinucleated cells with prominent macronucleoli (Image 1C) and characteristic positivity for PAX-5 weakly (Image 1D), CD30 (Image 1E), and CD15 (Image 1F), consistent with Hodgkin Reed-Sternberg (HRS) cells. The patient received praziquantel and a chemotherapy regimen consisting of cyclophosphamide, vincristine sulfate, prednisone, and dacarbazine. Concurrent classic Hodgkin lymphoma (CHL) and schistosomiasis are exceedingly rare. Both diseases show prominent reactive background inflammation with scant admixed diagnostic cells, and can mimic each other on small biopsies where HRS cells or ova are infrequent. Schistosomiasis is a common helminthic infection in tropical and subtropical countries acquired by contact with contaminated freshwater. S. mansoni is distinguishable from Schistosoma haematobium and Schistosoma japonicum by its large lateral spine (Image 1B) and predilection for infecting gastrointestinal organs. Most CHL in developing countries, including the current case, show evidence of Epstein-Barr virus infection (not shown). CHL is characterized by near-universal amplification of chromosome 9p24.1 and consequently, PD-L1/PD-L2 overexpression.1-4 In rare instances, the activation of PD-1 signaling and associated T cell exhaustion in the tumor microenvironment of CHL may provide a favorable milieu for concomitant parasitic infections. Nothing to report.
Abstract 12428: Caffeine Contained in a Cup of Coffee Ameliorates Microvascular Endothelial Function in Healthy Subjects
Authors: Masato Tsutsui, Katsuhiko Noguchi, Toshihiro Matsuzaki, Mayuko Sakanashi, Junko Nakasone, Matao Sakanashi, Yusuke Ohya
Journal: Circulation (2013)

Background: Coffee is the most widely consumed beverage in the world. Coffee contains a variety of pharmacological ingredients, including caffeine, and it has long been argued whether coffee drinki...
The trial that launched millions of mesh implant procedures: did money compromise the outcome?
Authors: Jonathan Gornall
Journal: BMJ (2018)

Vaginal mesh implants are currently suspended in the NHS pending the findings of a major government review. <b>Jonathan Gornall</b> goes in search of the obstetrician who invented mesh and uncovers how the original evidence was mired in a multimillion pound deal, industry funded research, and undisclosed conflicts of interest
Abstract 15883: Home-Time as a Novel Post-Discharge Outcome for Patients Hospitalized With Heart Failure
Authors: Stephen Greene, Nancy Luo, Robert J Mentz, Chantelle Hardy, Warren K Laskey, Paul A Heidenreich, Clyde W Yancy, Adrian Hernandez, Lesley Curtis, Pamela N Peterson, Chun-Lan Chang, Stuart Turner, Emily C O'Brien, Gregg C Fonarow, Bradley G Hammill
Journal: Circulation (2017)

Introduction: Surveys of patients with cardiovascular disease have suggested that home-time—being alive and out of a healthcare institution—is a highly prioritized outcome. This novel measure has...
Qualitative assessment of the brief pain inventory (BPI) “pain at its worst in the last 24 hours” item to support assessment of pain as a clinical trial endpoint in metastatic castrate resistant prostate cancer (mCRPC) per FDA labeling standards.
Authors: Antonia V. Bennett, Thomas Michael Atkinson, Narre Heon, Bridget O'Keeffe, Christian Scheffold, Frauke Schimmoller, Ethan M. Basch
Journal: Journal of Clinical Oncology (2013)

e16018 Background: Pain is common in men with mCRPC and can substantially impair function and quality of life. For assessment of pain as a clinical trial endpoint, substantial validation work has been conducted on the BPI “pain at its worst in the last 24 hours” item, but additional qualitative study of patient understanding of this item is necessary to fully meet FDA labeling standards. Methods: Twenty-six patients with mCRPC in a non-randomized expansion cohort (N=144) of phase II study XL184-203 were interviewed to confirm their comprehension of the BPI “pain at its worst in the last 24 hours” item, and elicit their interpretation of points on the 0-10 response scale to establish levels of intra-patient pain rating consistency. Patient descriptions were evaluated and further compared with previously identified associations between pain severity and pain interference ratings. Results: Patients (median age = 68; range 44-81) had ECOG performance status of 0 (38%) and 1 (62%). Nearly all patients answered the question as intended – by considering the past 24 hours (72%; 18% did not specify); including non-cancer related pain (96%); and reporting pain experienced with analgesia (100%). Patients described pain of “2” as relatively mild, noticeable, and not limiting; pain of “5” as moderate and limiting activity; and pain of “8” as severe and more or less incapacitating. Interpretation of the response scale was highly consistent both among patients and in comparison to levels of pain severity and interference identified in previous large statistical analyses. Conclusions: This study provides important qualitative support for the use of the BPI “pain at its worst in the last 24 hours” item to assess pain per FDA labeling standards in men with mCRPC. Consistent with prior qualitative work, these results confirm this item is well understood by patients. The interpretation of the response scale is remarkably consistent among patients, as well as with results from large statistical analyses, demonstrating the reliability of this item to assess patient-reported pain in cancer trials.
THU0528 The relief of chronic low back pain (CLBP) immediately after one session of low level laser acupuncture therapy (LLLAT)
Authors: D. Houssien, A. Houssien
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Low-level Laser acupuncture therapy (LLLAT) is defined as the stimulation of acupuncture points with low-intensity, laser irradiation and is widely used in treating musculoskeletal pain. <h3>Objectives</h3> To determine whether the use of a single session of LLLAT for Chronic Low Back Pain (CLBP) will result in better outcome than using acupuncture alone. <h3>Methods</h3> 40 patients with CLBP were randomly assigned to two treatment groups: G1 (Acupuncture; 20 patients) and G2 (laser acupuncture; 20 patients). All patients received a single session only. The Acupuncturists inserted a stainless steel needle in local low back (Du3,4, UB23,5,6), distal (UB36, 40,54,7,8,60, GB30,1,4, Li4) and auricular points. laser-acupuncture treatment with a 20 Hz 200 mW 820 nm Gallium Aluminium Arsenide diode laser was used the same previous points. Pain intensity was assessed on a 100 mm visual analogue scale (VAS). The lumbar range of motion was measured by fingertip-to-floor method. A physiotherapist, who was blinded to treatment assignment, evaluated the patients immediately before and after treatment as well as 4, 12 and 24 weeks later. <h3>Results</h3> Immediately after the completion of treatment, the mean VAS dropped from 78 to 66 mm in the acupuncture group<b> (</b>G1) but increased at the follow up visits to 76 mm after 24 weeks. In contrast, VAS scores decreased from 80 to 48 mm in the laser acupuncture group. Although it increased in the follow up visits 60 mm after 24 weeks, it remained significantly better (24 mm P&lt;0.0001) than at the initial assessment. The mean of fingertips and floor distance decreased significantly in G2 from 41 cm to 15 cm immediately after the completion of the first session (the difference from baseline was 26 cm) compared to a decrease from 44 to 35 after the first session in G1. Forward flexion of the lumbar spine improvement remained stable between the first assessment and the other four assessments in patients exposed to prayers with the difference between the baseline and 24 week assessments highly significant (p&lt;0.0001) compared to G1 (p&gt;0.05). <h3>Conclusions</h3> Both measures were decreased in both groups but laser acupuncture resulted in a significant improvement in functional and symptomatic outcomes in this group of patients with CLBP even after 24 weeks follow up. <h3>Disclosure of Interest</h3> None declared
Comparing metastatic (M) young onset (YO) colorectal cancer (CRC) with average onset (AO): Do they differ clinically and genetically?
Authors: G. Dos Santos Fernandes, W. Chatila, R. Yaeger, R. Mendelsohn, Z. Stadler, N.H. Segal, A. Varghese, D. Reidy, L. Diaz, J. Shia, E. Vakiani, J. Hechtman, N. Schultz, M. Berger, D. Hyman, D. Solit, L. Saltz, J. Garcia Aguilar, A. Cercek
Journal: Annals of Oncology (2018)
Anthony J Winterton
Authors: N Whyatt
Journal: BMJ (2018)

Anthony J Winterton (“Tony”) was born in Leicester and educated at Wyggeston School, also in Leicester. He read medicine at St Mary’s Hospital Medical School in London, where he played a great deal of rugby. During house jobs and senior house jobs in Nottingham he developed a lifelong interest in obstetrics. In 1956 he joined the New Road practice in …
Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland
Authors: Miikka Korja, Rahul Raj, Karri Seppä, Tapio Luostarinen, Nea Malila, Matti Seppälä, Hanna Mäenpää, Janne Pitkäniemi
Journal: Neuro-Oncology (2018)

We assessed population-level changes in glioblastoma survival between 2000 and 2013 in Finland, with focus on elderly patients (>70 y) in order to assess if changes in treatment of glioblastoma are reflected also in population-based survival rates. We identified all patients (age ≥18 y) from the Finnish Cancer Registry (FCR) with a histopathological diagnosis of primary glioblastoma in 2000–2013. Patients were followed up until December 2015. The accuracy of register-based search of glioblastoma patients was internally validated. We report age-standardized relative survival ratios and relative excess risks (RERs) of death in 2000–2006 (pre-period) and 2007–2013 (post-period). We identified 2045 glioblastoma patients from the FCR. The accuracy of the FCR-based search was 97%. Median age was 63.3 years, and 42% were women. Incidence increased on average by 1.6% (P = 0.004) and median age by 0.4 years per calendar year. Between the pre- and post-periods, the proportion of patients >70 years increased from 24% to 27%. In >70-year-old patients, the median survival time increased from 3.6 months in 2000–2006 to 4.5 months in 2007–2013 (RER 0.82, 95% CI: 0.68–0.98). In ≤70-year-old patients, the median survival time increased from 9.3 months in 2000–2006 to 11.7 months in 2007–2013 (RER 0.74, 95% CI: 0.67–0.82). Despite the increased proportion of elderly glioblastoma patients, population-level survival of glioblastoma patients has improved since the year 2000. However, increasing incidence, increasing age of patients, and poor survival in elderly are alarming, and future studies should perhaps focus more on elderly.
In vivo β-catenin attenuation by the integrin α5-targeting nano-delivery strategy suppresses triple negative breast cancer stemness and metastasis
Authors: Yunfei Li, Yajuan Xiao, Hsuan-Pei Lin, Derek Reichel, Younsoo Bae, Eun Y. Lee, Yiguo Jiang, Xuefei Huang, Chengfeng Yang, Zhishan Wang
Journal: Biomaterials (2018)
Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors
Authors: Ivana Yen, Frances Shanahan, Mark Merchant, Christine Orr, Thomas Hunsaker, Matthew Durk, Hank La, Xiaolin Zhang, Scott E. Martin, Eva Lin, John Chan, Yihong Yu, Dhara Amin, Richard M. Neve, Amy Gustafson, Avinashnarayan Venkatanarayan, Scott A. Foster, Joachim Rudolph, Christiaan Klijn, Shiva Malek
Journal: Cancer Cell (2018)
Incidence of clinically significant toxicities in patients with high endoxifen concentrations
Authors: S.L. Groenland, A.B. Sanchez-Spitman, D.J.A.R. Moes, S.L. Koolen, V.O. Dezentjé, N. van Erp, R.H.J. Mathijssen, H.-J. Guchelaar, A.D.R. Huitema, N. Steeghs
Journal: Annals of Oncology (2018)